| Title | Preexisting chronic conditions for fatal outcome among SFTS patients: An observational Cohort Study |
| Authors | Zhang, Shao-Fei Yang, Zhen-Dong Huang, Mao-Lin Wang, Zhi-Bo Hu, Yuan-Yuan Miao, Dong Dai, Ke Du, Juan Cui, Ning Yuan, Chun Li, Hao Li, Xiao-Kun Zhang, Xiao-Ai Zhang, Pan-He Mi, Xian-Miao Lu, Qing-Bin Liu, Wei |
| Affiliation | Beijing Inst Microbiol & Epidemiol, State Key Lab Pathogen & Biosecur, Beijing, Peoples R China 990 Hosp Chinese Peoples Liberat Army Joint Logis, Xinyang, Peoples R China Peking Univ, Sch Publ Hlth, Dept Laboratorial Sci & Technol, Beijing, Peoples R China Beijing Key Lab Vector Borne & Nat Focus Infect D, Beijing, Peoples R China |
| Issue Date | 2019 |
| Publisher | PLOS NEGLECTED TROPICAL DISEASES |
| Abstract | Severe fever with thrombocytopenia syndrome (SFTS) is an emerging infectious disease that is caused by a novel bunyavirus SFTSV. Currently our knowledge of the host-related factors that influence the pathogenesis of disease is inadequate to allow prediction of fatal outcome. Here we conducted a prospective study of the largest database on the SFTS patients, to identify the presence of comorbidities in SFTS, and estimate their effect on the fatal outcome. Among 2096 patients eligible for inclusion, we identified nine kinds of comorbidities, from which hyperlipidemia (12.2%; 95% CI: 10.8%-13.6%), hypertension (11.0%; 95% CI: 9.6%-12.3%), chronic viral hepatitis (CVH) (9.3%; 95% CI: 8.1%-10.5%), and diabetes mellitus (DM) (6.8%; 95% CI: 5.7%-7.9%) were prevalent. Higher risk of death was found in patients with DM (adjusted OR = 2.304; 95% CI: 1.520-3.492; P<0.001), CVH (adjusted OR = 1.551; 95% CI: 1.053-2.285; P = 0.026) and chronic obstructive pulmonary diseases (COPD) (adjusted OR = 2.170; 95% CI: 1.215-3.872; P = 0.009) after adjusting for age, sex, delay from disease onset to admission and treatment regimens. When analyzing the comorbidities separately, we found that the high serum glucose could augment diseases severity. Compared to the group with max glucose < 7.0 mmol/L, patients with glucose between 7.0-11.1 mmol/L and glucose 11.1 mmol/L conferred higher death risk, with the adjusted OR to be 1.467 (95% CI: 1.081-1.989; P = 0.014) and 3.443 (95% CI: 2.427-4.884; P<0.001). Insulin therapy could effectively reduce the risk of severe outcome in DM patients with the adjusted OR 0.146 (95% CI: 0.058-0.365; P<0.001). For CVH patients, severe damage of liver and prolongation of blood coagulation time, as well as high prevalence of bleeding phenotype were observed. These data supported the provocative hypothesis that treating SFTS related complications can attain potentially beneficial effects on SFTS. Author summary SFTS now brings about a substantial global public health concern. Preexisting chronic conditions were thought to increase risk of severe SFTSV infections, however with sparse data mining efforts. In this study, we quantified the frequency of chronic comorbidities in SFTS, estimated their contribution to disease severity, and separately evaluated the effect from diabetes mellitus and chronic viral hepatitis on resulting in fatal outcome. |
| URI | http://hdl.handle.net/20.500.11897/548553 |
| ISSN | 1935-2735 |
| DOI | 10.1371/journal.pntd.0007434 |
| Indexed | SCI(E) EI |
| Appears in Collections: | 公共卫生学院 |
